Merck Highlights the P-IIb/III (MK-1654-004) Study Data of Clesrovimab to Prevent RSV Disease in Healthy Preterm and Full-term Infantsat IDWeek 2024
Shots:
- The P-IIb/III (MK-1654-004) trial assessed clesrovimab (105mg, IM) vs PBO to prevent RSV disease in healthy preterm & full-term infants (n=3,632; birth to 1yr.) in their 1st season
- Study showed reduced incidence of RSV-related MALRI requiring ≥1 indicator of LRI by 60.4%, RSV-related hospitalizations by 84.2%, RSV-related LRI hospitalizations by 90.9% & severe MALRI by 91.7%; post hoc analysis depicted a reduced incidence of severe MALRI (requiring ≥2 indicators of LRI) by 88.0% post 5mos.
- Merck also featured P-III (MK-1654-007) study data of clesrovimab vs palivizumab in infants & children, showing 3.6% vs 3% rate of RSV-related MALRI requiring ≥1 indicator of LRI & 1.3% vs 1.5% rate of RSV-related hospitalizations post 5mos.
Ref: Merck | Image: Merck
Related News:- Merck Reports the P-IIb/III Study Data of Clesrovimab (MK-1654) to Prevent RSV Disease in Infants
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
